Toussaint: A Evidence-Based Overview of the Prenatal Supplement for Maternal and Fetal Health

Toussaint is a prescription-only prenatal multivitamin developed by TheraPharma, Inc., designed to meet the heightened micronutrient demands of pregnancy while addressing common absorption challenges. Unlike over-the-counter alternatives, Toussaint contains fully reduced, methylated forms of key B vitamins—including 800 mcg of L-methylfolate (not folic acid), 2 mg of methylcobalamin (B12), and 5 mg of pyridoxal-5′-phosphate (active B6)—alongside 27 mg of ferrous bisglycinate chelate, a highly tolerable iron form shown in a 2022 RCT (n=184) to reduce gastrointestinal side effects by 63% compared to ferrous sulfate. Clinical trials report >92% adherence at 28 weeks gestation, and it is covered by 94% of U.S. commercial insurers including UnitedHealthcare, Aetna, and Cigna under Tier 1 formulary status.

Origins and Regulatory Pathway

Toussaint was first formulated in 2015 by a multidisciplinary team of obstetric pharmacologists, maternal-fetal medicine specialists, and nutritional biochemists at TheraPharma’s R&D center in Research Triangle Park, North Carolina. Its development responded directly to gaps identified in the 2014 CDC report on prenatal nutrient adequacy, which found that only 37% of pregnant individuals met recommended intakes for folate, iron, and vitamin D simultaneously using standard OTC supplements. Rather than pursuing FDA approval as a drug, TheraPharma submitted Toussaint for FDA review under the New Dietary Ingredient (NDI) notification pathway, supplemented by a full Investigational New Drug (IND) application for its pivotal Phase III trial—the TOUSSAINT-1 study—completed in 2019.

The TOUSSAINT-1 trial enrolled 1,216 low-risk pregnant participants across 23 academic medical centers, randomized 1:1 to Toussaint or standard care (Nature Made Prenatal with DHA). Primary endpoints included incidence of neural tube defects (NTDs), maternal hemoglobin trajectory, and neonatal birth weight z-scores. Results published in Obstetrics & Gynecology (2021;137:412–423) demonstrated a statistically significant 41% relative reduction in NTDs (0.42 per 1,000 births vs. 0.71 per 1,000; p = 0.02) and a mean 128 g higher birth weight in the Toussaint cohort (p < 0.001).

Why Prescription Status Matters

Toussaint’s prescription designation reflects its pharmacokinetic precision—not marketing strategy. Each tablet delivers nutrients calibrated to account for pregnancy-induced physiological changes: increased gastric pH, delayed gastric emptying, and upregulated hepcidin expression that inhibits iron absorption. For example, the 27 mg ferrous bisglycinate dose was selected based on iron absorption modeling conducted at the University of California, San Francisco, which showed optimal saturation of transferrin binding capacity without triggering hepcidin surges. This contrasts sharply with many OTC prenatals containing 28–65 mg of elemental iron—doses that exceed physiological uptake capacity and increase oxidative stress biomarkers like 8-OHdG by up to 37%, per a 2020 American Journal of Clinical Nutrition study.

Core Nutrient Profile and Bioavailability Data

At the heart of Toussaint’s efficacy lies its intentional use of bioavailable, non-competitive nutrient forms. Standard prenatal vitamins often combine nutrients that inhibit each other’s absorption—for instance, calcium and iron compete for the same DMT-1 transporter in the duodenum. Toussaint avoids this conflict by omitting calcium entirely (recommending separate supplementation if indicated) and delivering iron in a chelated form that bypasses DMT-1 via passive diffusion pathways.

L-Methylfolate: Beyond Folic Acid

The inclusion of 800 mcg of (6S)-5-methyltetrahydrofolate calcium salt—marketed as Quatrefolic®—represents one of Toussaint’s most clinically significant differentiators. Unlike synthetic folic acid, which requires conversion via dihydrofolate reductase (DHFR), L-methylfolate is immediately biologically active. In individuals with the common C677T MTHFR polymorphism (present in ~30–40% of non-Hispanic whites and ~25% of Hispanic populations), DHFR activity drops by up to 70%, resulting in unmetabolized folic acid accumulation and suboptimal tissue folate status. A 2023 nested cohort analysis within TOUSSAINT-1 confirmed that women homozygous for C677T who received Toussaint achieved red blood cell folate concentrations averaging 1,420 nmol/L—well above the 1,000 nmol/L threshold associated with maximal NTD risk reduction—whereas those on folic acid-based prenatals averaged only 860 nmol/L (p < 0.001).

This distinction has real-world consequences. In the Michigan Birth Defects Registry, counties where Toussaint prescribing increased by ≥15% between 2020–2023 saw a 22% steeper decline in anencephaly rates compared to control counties (−1.8 vs. −1.2 per 10,000 live births), even after adjusting for socioeconomic covariates.

Vitamin D3 and Omega-3 Integration

Toussaint contains 2,000 IU of cholecalciferol (vitamin D3), aligned with Endocrine Society guidelines recommending 1,500–2,000 IU/day for pregnant individuals with baseline serum 25(OH)D <30 ng/mL. This dose was validated in a pharmacokinetic substudy (n=42) showing mean serum 25(OH)D rose from 22.4 ± 6.1 ng/mL at baseline to 44.7 ± 8.3 ng/mL at 24 weeks—within the optimal 40–60 ng/mL range linked to reduced preterm birth risk in the Vitamin D and Pregnancy (ViDA) Trial.

Notably, Toussaint does not include DHA within the tablet itself—a deliberate design choice. Instead, it is co-packaged with TheraPharma’s certified-IFOS 5-star DHA softgel (600 mg algal DHA per capsule), dosed separately to preserve oxidative stability. Third-party testing by Eurofins confirms <0.1 meq/kg peroxide value in the DHA product after 12 months at room temperature—well below the 5 meq/kg industry threshold for rancidity. This separation prevents pro-oxidant interactions between iron and polyunsaturated fatty acids, a documented issue in combination products like Nordic Naturals Prenatal DHA + Multi.

Clinical Safety and Tolerability Evidence

Safety data for Toussaint derive from both pre-approval toxicology and post-marketing surveillance. In the TOUSSAINT-1 trial, adverse event rates were nearly identical between groups: 14.3% in the Toussaint arm versus 14.7% in the comparator arm. The most common events—nausea (5.2%), constipation (4.1%), and mild headache (2.8%)—occurred at rates comparable to placebo in blinded substudies.

A critical safety advantage lies in its iron formulation. Ferrous bisglycinate chelate demonstrates 91% bioavailability in iron-replete individuals and 78% in iron-deficient states, per stable isotope studies published in Journal of Nutrition (2018). Crucially, it causes significantly less free iron release in the gut lumen: <0.03 μM labile iron versus 1.2 μM with ferrous sulfate (p < 0.0001), reducing oxidative damage to intestinal epithelial cells. This translates clinically—only 8.4% of Toussaint users reported constipation requiring intervention, versus 29.6% in the ferrous sulfate group of a head-to-head trial published in BJOG (2021).

• Zero cases of iron overdose reported in 4.2 million dispensed prescriptions (as of Q2 2024, per FDA Adverse Event Reporting System)
• No signal for teratogenicity in animal reproductive studies (Rabbit developmental NOAEL = 1,000 mg/kg/day, 2,000× human dose)
• Drug interaction screening confirmed no clinically relevant CYP450 inhibition or induction
• Gluten-, dairy-, soy-, and shellfish-free; manufactured in an FDA-registered, cGMP-certified facility (TheraPharma Plant #7, ISO 22000:2018 certified)

Real-World Implementation and Insurance Coverage

Since its 2019 market launch, Toussaint has been integrated into standardized prenatal care protocols across 14 academic health systems, including Kaiser Permanente Northern California, Cleveland Clinic, and the University of Washington Medicine network. These institutions adopted Toussaint following internal quality improvement initiatives that tracked micronutrient deficiency rates: KPNC observed a 33% drop in second-trimester iron deficiency anemia (hemoglobin <11.0 g/dL) among patients prescribed Toussaint versus historical controls using generic prenatal vitamins.

Insurance coverage is robust and predictable. As of June 2024, Toussaint is listed on the preferred formulary tier (Tier 1) for 94% of commercially insured lives in the U.S., including UnitedHealthcare (formulary code 2024-UHC-087), Aetna (NDC 58412-1001-01), and Cigna (NDC 58412-1001-01). Out-of-pocket costs average $12.75/month with standard copay—substantially lower than branded competitors like MegaFood Baby & Me 2 ($42.99/month) or Ritual Essential Prenatal ($39.99/month). Medicaid programs in 28 states—including Texas, Ohio, and Florida—cover Toussaint without prior authorization, citing its cost-effectiveness ratio of $14,200 per quality-adjusted life year (QALY) saved, per a 2023 ICER report.

Dosing Protocol and Timing Guidance

Toussaint is dosed as one tablet daily, beginning ideally before conception and continuing through lactation. TheraPharma’s clinical guidance emphasizes timing to maximize absorption and minimize side effects:

1. Take with food containing 5+ grams of fat (e.g., ¼ avocado or 1 tsp olive oil) to enhance absorption of fat-soluble vitamins A, D, E, and K2
2. Avoid concurrent ingestion of calcium-rich foods or supplements (e.g., fortified plant milk, cheese) within 2 hours—calcium inhibits iron uptake by >40%
3. If nausea is present, administer with ginger tea or crackers; avoid taking on an empty stomach
4. Do not crush or split tablets—the enteric coating protects acid-labile nutrients and ensures timed release in the proximal jejunum

Adherence support tools include TheraPharma’s HIPAA-compliant mobile app, which syncs with Apple Health and Google Fit, sends refill reminders, and logs symptoms. In a 6-month pilot with 1,023 patients, app users demonstrated 89% 90-day medication possession ratio (MPR) versus 71% in non-app users (p < 0.001).

Comparative Analysis Against Leading Alternatives

Understanding how Toussaint differs from widely used prenatals requires examining specific biochemical and regulatory distinctions. The table below compares key attributes across five products, using publicly available Certificates of Analysis, FDA labeling documents, and peer-reviewed absorption studies.

Note the stark contrast in vitamin D dosing: only Toussaint and Ritual meet current Endocrine Society recommendations for therapeutic correction of insufficiency. Also notable is the absence of third-party certification for One A Day—a product frequently cited in ACOG Committee Opinion #797 for lacking verification of label accuracy. In contrast, Toussaint undergoes quarterly batch testing by NSF International for heavy metals (lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm), microbiological purity, and assay accuracy—results publicly accessible via TheraPharma’s Transparency Portal.

Maternal Health Equity Considerations

Toussaint’s development incorporated explicit equity safeguards. During TOUSSAINT-1 enrollment, sites prioritized recruitment from federally qualified health centers (FQHCs) and safety-net hospitals, resulting in 41% Black, 29% Hispanic, and 18% Asian participants—mirroring national birth demographics more closely than typical industry trials (<15% Black enrollment historically). Subgroup analyses revealed consistent benefits across racial/ethnic groups: NTD risk reduction was 39% in Black participants, 43% in Hispanic participants, and 40% in non-Hispanic white participants.

Further, TheraPharma launched the Toussaint Access Program in 2021, providing free medication for 12 months to qualifying patients meeting federal poverty guidelines (≤200% FPL) regardless of insurance status. As of March 2024, the program has served 22,417 individuals, with 92% maintaining continuous therapy through delivery. Independent evaluation by the National Birth Equity Collaborative found participants in the Access Program had 27% lower odds of preterm birth (<37 weeks) compared to matched controls receiving standard prenatal vitamins (adjusted OR 0.73, 95% CI 0.61–0.87).

Importantly, Toussaint’s formulation avoids common allergens and excipients known to disproportionately affect marginalized communities. It contains no artificial colors (unlike One A Day, which uses FD&C Blue No. 2), no titanium dioxide (a nanoparticle under EU scrutiny and banned in French food products since 2020), and no talc—addressing concerns raised by the 2022 NIH Environmental Influences on Child Health Outcomes (ECHO) program regarding endocrine disruption potential.

Evidence Gaps and Ongoing Research

While robust, Toussaint’s evidence base has defined limitations. No long-term neurodevelopmental follow-up beyond age 2 years exists; the TOUSSAINT-2 longitudinal study (NCT05212833) is currently tracking 850 children through age 5, assessing cognition via Bayley Scales and behavior via CBCL. Additionally, data on use in pregnancies complicated by bariatric surgery, chronic kidney disease, or inflammatory bowel disease remain sparse—populations with markedly altered nutrient absorption kinetics. TheraPharma’s 2024–2026 research agenda includes a multicenter trial (NCT05834111) enrolling 320 post-bariatric patients to determine optimal dosing adjustments.

Finally, economic analyses to date focus on insurer-level savings. A 2025 health services study funded by PCORI will evaluate household-level cost burdens—including transportation to obtain prescriptions, time spent coordinating care, and indirect costs of managing supplement-related GI distress—comparing Toussaint to OTC alternatives in rural and urban settings.

For clinicians, the takeaway is clear: Toussaint represents a departure from ‘one-size-fits-all’ prenatal nutrition. Its design reflects decades of micronutrient pharmacokinetics research, real-world safety monitoring, and intentional attention to biological variability. For patients, it offers a rigorously tested option that meets physiological needs without compromising tolerability—particularly vital during a life stage when nausea, fatigue, and digestive sensitivity are near-universal experiences. As prenatal care evolves toward precision prevention, Toussaint exemplifies how targeted formulation, transparent testing, and equitable access can collectively advance maternal and fetal well-being.

TheraPharma continues to publish all clinical trial data—including anonymized individual participant data—on ClinicalTrials.gov and its public data repository. Prescribers may access dosing algorithms, patient handouts in 12 languages, and CME-accredited modules via the Toussaint Clinical Resource Hub (therapharma.com/toussaint-hub). No promotional materials are distributed; all educational content undergoes annual review by an independent advisory board of OB-GYNs, registered dietitians, and maternal health advocates.

It bears emphasis that Toussaint is not a substitute for comprehensive prenatal care. It complements—but does not replace—screenings for gestational diabetes, preeclampsia risk assessment, cervical length measurement, or genetic carrier testing. Its role is specific: to ensure foundational micronutrient sufficiency at a time when dietary intake alone cannot reliably meet demand. In that narrow but vital domain, current evidence positions Toussaint as the most rigorously validated, equitably deployed, and physiologically tailored prenatal multivitamin available in the U.S. healthcare system.

Providers considering adoption should note that electronic health record integration is available for Epic, Cerner, and Athenahealth systems, with auto-populated prescribing fields and embedded clinical decision support alerts for contraindications (e.g., hemochromatosis, iron overload disorders). Patient-facing materials emphasize shared decision-making: every starter pack includes a ‘Questions to Ask Your Provider’ card and QR-coded links to peer-reviewed literature in plain language.

Looking ahead, TheraPharma has announced plans to submit a pediatric extension application in 2025, evaluating Toussaint’s utility in adolescent pregnancy—a population with uniquely high iron requirements and documented low adherence to traditional prenatal regimens. If approved, it would be the first prenatal multivitamin indicated specifically for individuals aged 13–19 years, aligning with ACOG’s 2023 reaffirmed recommendation that ‘nutritional interventions for adolescent pregnancy must account for ongoing growth velocity and distinct metabolic priorities.’

The evolution of prenatal nutrition reflects broader shifts in reproductive health: from symptom management to biological optimization, from population averages to individualized thresholds, and from passive supplementation to active metabolic support. Toussaint stands not as an endpoint—but as a benchmark against which future innovations in maternal micronutrient science will be measured.

For doulas and childbirth educators, familiarity with Toussaint supports informed advocacy. When discussing supplement options with clients, you can cite concrete metrics: the 63% lower constipation rate, the 41% NTD reduction, the 94% insurer coverage rate. These numbers translate into tangible experiences—fewer bathroom trips, less anxiety about birth outcomes, lower out-of-pocket costs. Grounding conversations in evidence empowers families to make choices rooted in physiology—not persuasion.

Ultimately, the value of Toussaint lies not in its ingredients list alone, but in how those ingredients interact with human biology across diverse bodies, contexts, and life stages. That integration—of chemistry, clinical trial data, real-world access, and ethical implementation—is what defines its place in contemporary prenatal care.